Skip to main content
SpringerLink
Log in

Duration of Neuroleptic Maintenance Treatment

  • Conference paper
Guidelines for Neuroleptic Relapse Prevention in Schizophrenia

Abstract

The question of the optimal duration of neuroleptic maintenance treatment of schizophrenia is naturally intimately linked with the question of which patients are to receive this maintenance treatment (see review by Johnson, this volume) as well as the question whether reliable predictors of the individual relapse risk are available (see review by Marder, this volume). Thus a certain amount of overlap with these other reviews cannot be avoided.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • APA (1980) Tardive dyskinesia: summary of a task force report of the American Psychiatric Association. Am J Psychiatry 137:10

    Google Scholar 

  • Bosch G, Pietzcker A (1975) Anhang zum Bericht über die Lage der Psychiatrie in der Bundesrepublik Deutschland, Bundestag, Drucksache 7/4201, pp 344–360

    Google Scholar 

  • Casey DE (1987) Tardive dyskinesia. In: Meltzer HY (ed) Psychopharmacology. The third generation of progress. Raven, New York

    Google Scholar 

  • Cheung HK (1981) Schizophrenics fully remitted on neuroleptics for 3–5 years, to stop or continue drugs? Br J Psychiatry 138:490–494

    Article  PubMed  CAS  Google Scholar 

  • Chien CP (1975) Drugs and rehabilitation in schizophrenia. In: Greenblatt M (ed) Drugs in combination with other therapies. Grune and Stratton, New York, pp 13–34

    Google Scholar 

  • Crow TJ, McMillan JF, Johnson AL, Johnstone EC (1986) The Northwick Park study of first episodes of schizophrenia: II. A randomized controlled trial of prophylactic neuroleptic treatment. Br J Psychiatry 148:120–127

    Article  PubMed  CAS  Google Scholar 

  • Davis JM (1980) Antipsychotic drugs. In: Kaplan HI, Freedman AM, Sadock BJ (ed) Comprehensive textbook of psychiatry/III. Williams and Wilkins, Baltimore

    Google Scholar 

  • Dencker SJ, Lepp M, Malm U (1980) Do schizophrenics well adapted in the community need neuroleptics? A depot neuroleptic withdrawal study. Acta Psychiatr Scand (Suppl) 279:64–76

    CAS  Google Scholar 

  • Gaebel W, Pietzcker A (1983) Indikation zur neuroleptischen Langzeitmedikation — Standardverfahren oder individualprognostisch geleitete Intervention? Nervenarzt 54:467–476

    PubMed  CAS  Google Scholar 

  • Hogarty GE, Goldberg SC, Collaborative Study Group (1974) Drug and sociotherapy in the aftercare of schizophrenic patients: one year relapse rates. Arch Gen Psychiatry 28:54–64

    Article  Google Scholar 

  • Johnson DAW (1976) The duration of maintenance therapy in chronic schizophrenia. Acta Psychiatr Scand 53:298–301

    Article  PubMed  CAS  Google Scholar 

  • Johnson DAW (1979) Further observations on the duration of depot neuroleptic maintenance therapy in schizophrenia. Br J Psychiatry 135:524–530

    Article  PubMed  CAS  Google Scholar 

  • Johnson DAW (1981a) Studies of depressive symptoms in schizophrenia. I. The prevalence of depression and its possible causes. Br J Psychiatry 139:9–101

    Article  Google Scholar 

  • Johnson DAW (1981b) Epidemiological evaluation of mainenance antipsychotic treatment. In: Tognoni G, Bellantuono C, Lader M (eds) Epidemiological impact of psychotropic drugs. Biomedical Press, Elsevier, Amsterdam

    Google Scholar 

  • Johnson DAW (1984) Observations on the use of long-acting depot neuroleptic injections in the maintenance therapy of schizophrenia. J Clin Psychiatry 5, Sec 2:13–21

    Google Scholar 

  • Johnson DAW (1988) Dose reduction, relapse and compliance. In: Barnes TRE (ed) Depot neuroleptics: a consensus, Antwerp 19 Nov 87. Mediscript, London, pp 53–59

    Google Scholar 

  • Kane JM (ed) (1984) Drug maintenance strategies in schizophrenia. American Psychiatric Press, Washington D.C.

    Google Scholar 

  • Kane JM, Rifkin A, Quitkin F, Naya D, Ramos-Lorenzi J (1982) Fluphenazine versus placebo in patients with remitted, acute first episode schizophrenia. Arch Gen Psychiatry 39:70–73

    Article  PubMed  CAS  Google Scholar 

  • Kane JM, Woerner M, Lieberman J (1985) Tardive dyskinesia: prevalence, incidence, and riks factors. In: Casey DE, Chase TN, Christensen AV, Gerlach J (eds) Dyskinesia — research and treatment. Springer, Berlin Heidelberg New York (Psychopharmacology Series, vol 2)

    Google Scholar 

  • Kane JM, Woerner M, Borenstein M, Wegner J, Lieberman J (1986) Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol Bull 22:254–258

    PubMed  CAS  Google Scholar 

  • Kissling W (1988) Consensus regarding indication for prophylactic neuroleptic treatment — necessary, but unattainable? In: Barnes TRE (ed) Depot neuroleptics — a consensus. Antwerp, 19 Nov 87. Mediscript, London, pp 41–46

    Google Scholar 

  • Leff JP, Wing JK (1971) Trial of maintenance therapy in schizophrenia. Br Med J 3:559–604

    Article  Google Scholar 

  • Marsden CD (1985) Is tardive dyskinesia a unique disorder? In: Casey DE, Chase TN, Christensen AV, Gerlach J (eds) Dyskinesia — research and treatment. Springer, Berlin Heidelberg New York (Psychopharmacology series, vol 2)

    Google Scholar 

  • Möller HJ, von Zerssen D (1981) Depressive Symptomatik im stationären Behandlungsverlauf von 280 schizophrenen Patienten. Pharmacopsychiatrie 14:172–179

    Article  Google Scholar 

  • Müller P (ed) (1982) Zur Rezidivprophylaxe schizophrener Psychosen. Enke, Stuttgart

    Google Scholar 

  • Odejide OA, Aderounmu AF (1982) Double-blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patients. J Clin Psychiatry 43(5): 195–196

    PubMed  CAS  Google Scholar 

  • Putten T van, May PRA (1978) Akinetic depression’ in schizophrenia. Arch Gen Psychiatry 35:1101–1107

    Article  PubMed  Google Scholar 

  • Rifkin A, Quitkin F, Rabiner CJ, Klein DF (1977) Fluphenazine decanoate, oral fluphenazine and placebo in the treatment of remitted schizophenics: I. Relapse rates after one year. Arch Gen Psychiatry 34:43–47

    Article  PubMed  CAS  Google Scholar 

  • Troshinsky CH, Aaronson HG, Stone RK (1962) Maintenance phenothiazine in the aftercare of schizophrenic patients. Pennsylvania Psychiatric Q 2:11–15

    Google Scholar 

  • Wistedt B (1981) A depot neuroleptic withdrawal study: a controlled study of the clinical effects of the withdrawal of depot fluphenazine decanoate and depot flupenthixol decanoate in chronic schizophrenic patients. Acta Psychiatr Scand 64:65–84

    Article  PubMed  CAS  Google Scholar 

  • Wyatt RJ (1987) Introduction: side effects. In: Meltzer HY (ed) Psychopharmacology: the third generation of progress. Raven, New York

    Google Scholar 

Download references

Authors
  1. W. Kissling
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Psychiatrische Klinik und Poliklinik, Technischen Universität München, Ismaninger Straße 22, W-8000, München 80, Germany

    Werner Kissling

Rights and permissions

Reprints and permissions

Copyright information

© 1991 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Kissling, W. (1991). Duration of Neuroleptic Maintenance Treatment. In: Kissling, W. (eds) Guidelines for Neuroleptic Relapse Prevention in Schizophrenia. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-86922-8_17

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-86922-8_17

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-53985-8

  • Online ISBN: 978-3-642-86922-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation